Claim 1: a Pharmaceutical composition which comprises or is made of an inhibitor of a drug dpp4, check one or more Pharmaceutical Excipients and \/ or basic nucleophile and an agent to stabilize the inhibitor of dpp4 from degradation.Claim 3: the pharmaceutical composition according to claim 1, 2 or 3, wherein the drug is selected from the group consisting of Biguanides as metformin hydrochloride, tiazolidinonas as pioglitazone hydrochloride, statins Atorva Statin, and ARBS such as telmisartan.Claim 1: the pharmaceutical composition according to any one of claims 1 to 4, wherein the agent base or nucleophile and \/ or buffering substance is a basic amino acid with an amino Group and intramolecular Alkaline characteristics, including l-arginine L - L - lysine and histidineClaim 7: the pharmaceutical composition according to any one of claims 1 to 6, wherein the inhibitor is selected from the dpp4 vildagliptin and saxagliptin Alogliptin.Claim 1: the pharmaceutical composition according to any one of claims 1 to 6, wherein the inhibitor of dpp4 is the Free Base of 1 - [(4 - methyl - 2 - quinazolin - yl) methyl] - 3 - methyl - 4 - (2 - BUTYN - 1 - il) - 8 - (3 - (R) - amino - piperidin-1-yl) - xanthine.Reivindicacion 1: Una composicion farmacéutica caracterizada porque comprende o está hecha de un inhibidor de la DPP4, un fármaco acompanante, uno o más excipientes farmacéuticos y un agente nucleofilo y/o básico para estabilizar dicho inhibidor de la DPP4 frente a la degradacion. Reivindicacion 4: La composicion farmacéutica segun una cualquiera de las reivindicaciones 1 2 o 3, caracterizada porque el fármaco acompanante se selecciona del grupo que consiste en biguanidas como clorhidrato de metformina, tiazolidinonas como clorhidrato de pioglitazona, estatinas como atorvastatina, y BRA como telmisartán. Reivindicacion 5: La composicion farmacéutica segun una cualquiera de las reivindicaciones 1 a 4, caracterizada porque el agente nucleofilo y/o básico o la sustancia tamp
